B. Metzler seel. Sohn & Co. AG Cuts Stock Holdings in Gilead Sciences, Inc. $GILD

B. Metzler seel. Sohn & Co. AG reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 90,125 shares of the biopharmaceutical company’s stock after selling 8,102 shares during the quarter. B. Metzler seel. Sohn & Co. AG’s holdings in Gilead Sciences were worth $10,004,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Corundum Trust Company INC purchased a new stake in Gilead Sciences during the 3rd quarter valued at about $26,000. Howard Hughes Medical Institute bought a new position in Gilead Sciences during the 2nd quarter worth approximately $30,000. MTM Investment Management LLC increased its stake in Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 176 shares during the period. Kilter Group LLC bought a new stake in Gilead Sciences in the second quarter valued at approximately $33,000. Finally, Millstone Evans Group LLC lifted its position in Gilead Sciences by 58.7% in the third quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 118 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

GILD has been the topic of several recent analyst reports. HSBC raised their target price on shares of Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a report on Wednesday, December 10th. Truist Financial upped their price target on shares of Gilead Sciences from $145.00 to $152.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. JPMorgan Chase & Co. increased their price target on shares of Gilead Sciences from $150.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Wall Street Zen cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 23rd. Finally, Bank of America set a $162.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, February 11th. Twenty-three investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $156.72.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $144.08 on Monday. The business has a 50 day moving average of $138.29 and a 200 day moving average of $125.85. Gilead Sciences, Inc. has a 52 week low of $93.37 and a 52 week high of $157.29. The company has a market cap of $178.86 billion, a PE ratio of 21.28, a P/E/G ratio of 1.89 and a beta of 0.36. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. The business had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s payout ratio is presently 46.68%.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 115,640 shares of the business’s stock in a transaction dated Friday, January 23rd. The shares were sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the transaction, the chief executive officer owned 566,698 shares in the company, valued at $76,504,230. The trade was a 16.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the completion of the transaction, the insider directly owned 120,288 shares of the company’s stock, valued at approximately $18,577,278.72. The trade was a 18.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 309,280 shares of company stock worth $43,935,470 over the last ninety days. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.